IE
PRLD icon

Israel Englander’s Prelude Therapeutics PRLD Stock Holding History

Israel Englander’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5M Buy
844,993
+462,256
+121% +$2.01M ﹤0.01% 3088
2026
Q1 		$1.31M Buy
382,737
+231,740
+153% +$608K ﹤0.01% 4182
2025
Q4 		$438K Sell
150,997
-996,047
-87% -$1.68M ﹤0.01% 5033
2025
Q3 		$1.65M Buy
1,147,044
+898,621
+362% +$901K ﹤0.01% 4221
2025
Q2 		$201K Buy
248,423
+101,653
+69% +$88K ﹤0.01% 5360
2025
Q1 		$113K Sell
146,770
-315,785
-68% -$295K ﹤0.01% 5419
2024
Q4 		$590K Buy
462,555
+302,031
+188% +$401K ﹤0.01% 4616
2024
Q3 		$332K Buy
+160,524
New +$743K ﹤0.01% 5131
2024
Q2 		– Sell
-101,850
Closed -$483K – 6391
2024
Q1 		$483K Buy
101,850
+4,884
+5% +$19K ﹤0.01% 4849
2023
Q4 		$414K Buy
96,966
+33,099
+52% +$101K ﹤0.01% 4759
2023
Q3 		$197K Sell
63,867
-74,626
-54% -$280K ﹤0.01% 5131
2023
Q2 		$623K Buy
138,493
+1,974
+1% +$11.8K ﹤0.01% 4389
2023
Q1 		$778K Buy
136,519
+86,783
+174% +$529K ﹤0.01% 4311
2022
Q4 		$300K Sell
49,736
-10,690
-18% -$68.5K ﹤0.01% 5113
2022
Q3 		$399K Sell
60,426
-30,511
-34% -$206K ﹤0.01% 5137
2022
Q2 		$475K Buy
90,937
+51,626
+131% +$263K ﹤0.01% 4992
2022
Q1 		$271K Sell
39,311
-404,800
-91% -$3.7M ﹤0.01% 5629
2021
Q4 		$5.53M Buy
444,111
+403,260
+987% +$6.56M ﹤0.01% 2798
2021
Q3 		$1.28M Buy
40,851
+19,893
+95% +$644K ﹤0.01% 4416
2021
Q2 		$600K Buy
20,958
+7,455
+55% +$265K ﹤0.01% 5141
2021
Q1 		$585K Buy
+13,503
New +$896K ﹤0.01% 4693
2020
Q4 		– Sell
-189,573
Closed -$5.71K – 5509
2020
Q3 		$5.71K Buy
+189,573
New +$5.35M 0.01% 1720

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Israel Englander's PRLD Position: Q2 2026 in Review

Israel Englander increased its Prelude Therapeutics (PRLD) stake by 121% in Q2 2026, buying an estimated $2.01M and bringing the position to 844,993 shares worth $4.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3088.

Israel Englander first reported a position in PRLD in Q3 2020 and has held it in 22 quarters since. The position peaked at $5.53M in Q4 2021. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Israel Englander held 844,993 shares of Prelude Therapeutics worth $4.5M as of Q2 2026.
  • Israel Englander bought 462,256 Prelude Therapeutics shares in Q2 2026, an estimated $2.01M.
  • Prelude Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3088 holding.
  • Israel Englander first reported a position in Prelude Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • Israel Englander's Prelude Therapeutics position peaked at $5.53M in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.